A new way of thinking about metabolic health

Just a few weeks ago, a GLP1 medication was released in pill form for the first time, and McKenzie partner Lars Hartenstein says this kind of innovation is just the beginning. GLP1s, which help to lower blood sugar and reduce appetite, have already proven to be a game changer. Know that it's at the moment on track to be probably the biggest drug class we have ever seen? But despite the positive effects these drugs have had for many people, when it comes to overall metabolic health, they're not a magic bullet. It's not that this drug class is going to solve obesity or metabolic health.

It is a very important tool, the most important new tool for sure. This is the McKinsey Podcast, where we help you make sense out of the world's toughest business challenges. I'm your host for today, Roberta Fassaro. And we're here to talk about a recent McKinsey report titled A Path Toward a Metabolic Health Revolution. What makes metabolic health and obesity such a pressing global issue today?

Lars explains. Right now, approximately a billion of adults are living with obesity globally. And that's the cause of many, many health effects and creates a lot of diseases down the road. Therefore, obesity is a very big focus for everybody who is interested in global health essentially. What has changed is that we have new classes of drugs.

We already have this episode, so unlocking it is cheap and permanent: the full transcript (17 minutes, 2,612 words), segment and word-level timestamps, and .txt, .srt, .vtt and word-level JSON downloads, as many times as you like, forever.

No account needed, we create one from your checkout email. With credits it is 1 credit; packs start at 5 episodes for $3.49, and monthly plans are cheaper still.